United States v. Davaughn Ellis West

Court of Appeals for the Sixth Circuit·Decided January 13, 2026·No. 25-5024·Unpublished

Opinion

NOT RECOMMENDED FOR PUBLICATION File Name: 26a0024n.06

No. 25-5024

UNITED STATES COURT OF APPEALS FILED FOR THE SIXTH CIRCUIT Jan 13, 2026 KELLY L. STEPHENS, Clerk

)

UNITED STATES OF AMERICA, )

Plaintiff-Appellee, ) ON APPEAL FROM THE ) UNITED STATES DISTRICT v. ) COURT FOR THE EASTERN ) DISTRICT OF KENTUCKY DAVAUGHN ELLIS WEST, )

Defendant-Appellant. )

OPINION

)

Before: BATCHELDER, CLAY, and RITZ, Circuit Judges.

CLAY, Circuit Judge. Defendant Davaughn Ellis West was sentenced to 132 months in prison and 4 years of supervised release after he pleaded guilty to one count of distribution of 40 grams or more of fentanyl, in violation of 21 U.S.C. § 841(a)(1). On appeal, Defendant argues that his sentence is unreasonable. For the reasons set forth below, we AFFIRM the judgment of the district court.

I. BACKGROUND

A. Factual Background

Between approximately February and June 2022, Defendant Davaughn Ellis West conspired with Meagan Brittany Mounce and Anthony Trevell Norman to distribute oxycodone pills, methamphetamine, and fentanyl. Defendant and Norman worked together to acquire methamphetamine and fentanyl from multiple drug suppliers, and they provided those drugs to dealers in Pulaski and Madison Counties, Kentucky. Mounce was one such dealer.

From February to December 2022, the Federal Bureau of Investigation (“FBI”) utilized a cooperating source (“CS”) to purchase various quantities of oxycodone, fentanyl, and methamphetamine from Mounce, Norman, and Defendant. The CS initially purchased illegal drugs from Mounce. During an April 26, 2022 transaction with Mounce, the CS met Defendant and Norman when they delivered two ounces of fentanyl for the CS. Then, on May 10, 2022, the FBI used the CS to purchase 445.8 grams of methamphetamine from Defendant. In total, Defendant delivered 9,057.75 kilograms of converted drug weight to the CS.

B. Procedural History

On February 22, 2024, a federal grand jury returned an indictment against Defendant. The indictment charged Defendant with one count of attempt and conspiracy, two counts of knowingly or intentionally manufacturing, distributing, or dispensing, or possessing with intent to manufacture, distribute, or dispense, a controlled substance, and one count of aiding and abetting, in violation of 21 U.S.C. § 846, 21 U.S.C. § 841(a)(1), and 18 U.S.C. § 2, respectively.

Defendant signed a plea agreement and pleaded guilty to one count in violation of 21 U.S.C. § 841(a)(1). In exchange for his plea, the government agreed to move to dismiss the other counts against Defendant at his sentencing hearing.

The United States probation department then prepared a pre-sentence report (“PSR”). The PSR calculated Defendant’s base offense level at 32 with a three level reduction for acceptance of responsibility pursuant to U.S.S.G. § 3E1.1(a). With a criminal history category of V and total offense level of 29, Defendant’s proposed Guidelines range was 140 to 175 months.

Defendant raised several objections to the PSR. First, Defendant claimed his base offense level was incorrect because in the plea agreement, the parties did not agree to a quantity of narcotics determining the Guidelines calculations, and there was no evidence that any drugs were

transacted on May 10, 2022. Second, Defendant claimed that the May 10, 2022 transaction was not relevant conduct under U.S.S.G § 1B1.3(a)(2) to the § 841(a)(1) violation to which he had pleaded guilty. Third, as a result of his first two objections, Defendant claimed that his base offense level should be 24 with a Guidelines range of 70 to 87 months. Fourth, Defendant averred that a downward departure under U.S.S.G. § 4A1.3(b)(1) was warranted because half of his criminal history points came from prior possession of marijuana convictions.

The district court held Defendant’s sentencing hearing on January 3, 2025. At the hearing, the court allowed the government to present witnesses and evidence in response to Defendant’s objections. The government first presented the CS as a witness to testify as to his controlled drug transactions with Defendant, Mounce, and Norman. On direct examination and while referencing video footage of the CS’s interactions with Defendant, the CS testified that he had purchased one pound of methamphetamine from Defendant for $3,500 on May 10, 2022. In total, the transaction took approximately four to five hours to complete since Defendant left the CS in order to source the drugs. The CS also stated that he and Defendant had discussed the methamphetamine sale and $3,500 sale price during the April 26, 2022 drug transaction for two ounces of fentanyl.

On cross-examination, Defendant’s attorney questioned the CS’s sobriety during the two drug transactions and his motivations for assisting the FBI with the investigation. The CS admitted that he was a “[l]ittle bit” high during the April 26, 2022 controlled buy from taking a “nerve pill.” Sentencing Hr’g Tr., R. 118, PageID #513. He also stated that he was previously addicted to Suboxone for approximately three years prior to the transactions, but was no longer addicted when he was approached by the FBI to assist with the controlled buys. The CS stated that during the May 10, 2022 controlled buy, he was on Xanax because he was nervous about the transaction. When asked why he assisted the FBI, the CS cited the need to support his two children.

The government then presented FBI Special Agent Mike McLaughlin for examination.

Agent McLaughlin testified as to his supervisory role over the April 26, 2022 and May 10, 2022 controlled buys, as well as what the CS relayed to him about the CS’s conversations with Defendant about the drug transactions. Agent McLaughlin noted that the recording device used by the CS during the May 10, 2022 transaction “ran out of battery and . . . recording space” because the deal took so long. Id. at PageID #532–33. Thus, the video recording did not capture the part of the transaction when the CS actually received the drugs. The agent also testified, however, that the CS provided him the drugs from the May 10, 2022 transaction, which turned out to be 445.8 grams of methamphetamine after further laboratory testing.

The district court then heard argument on Defendant’s first objection. The court found the CS’s testimony to be credible; although the CS admitted to being on Xanax during the May 10, 2022 controlled buy, the court noted how “his testimony [was] not contradicted in any way” by the portions of the transaction the video recording captured. Id. at PageID #549. The court also noted that Agent McLaughlin, who it presumed was “experience[d] dealing with people who are compromised,” “[s]aw no indication” that the CS was compromised. Id. Thus, the court credited the CS’s testimony and the video tape recording to conclude that Defendant “was the author and completer of [the May 10, 2022] transaction.” Id. at PageID #550. The court therefore overruled Defendant’s first objection by concluding that the evidence supported the government’s claim that the transaction “involved a pound of crystal [meth] for $3,500.” Id.

The district court next considered Defendant’s second objection. It disagreed with Defendant’s claim that U.S.S.G. § 1B1.3(a)(2) “only applies when there are multiple offenses of conviction.” Id. at PageID #564. The court noted that the text of § 1B1.3(a)(2) was “clear and not ambiguous” since “[n]othing in the construction of . . . 1B1.3 or the general approach to the

guideline suggest[ed]” to the court that § 1B1.3(a)(2) “only applies when there are multiple offenses of conviction.” Id. The court further explained that § 1B1.3(a)(2)’s reference to “offenses of a character [for which § 3D1.2(d) would require grouping of multiple counts]” was simply a standard for the type of offense that would constitute “expanded relevant conduct.” Id. at PageID #564–65. Accordingly, the district court overruled Defendant’s second and third objections.

Free access — add to your briefcase to read the full text and ask questions with AI

United States v. Davaughn Ellis West, (6th Cir. 2026).

United States v. Davaughn Ellis West (United States v. Davaughn Ellis West) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

United States v. Anthony Hall, Jr.
373 F. App'x 588 (Sixth Circuit, 2010)
United States v. Olano
507 U.S. 725 (Supreme Court, 1993)
Kimbrough v. United States
552 U.S. 85 (Supreme Court, 2007)
Gall v. United States
552 U.S. 38 (Supreme Court, 2007)
United States v. David L. Shafer
199 F.3d 826 (Sixth Circuit, 1999)
United States v. Javier Aparco-Centeno
280 F.3d 1084 (Sixth Circuit, 2002)
United States v. Tony Richardson
437 F.3d 550 (Sixth Circuit, 2006)
United States v. Tracey Scott Esteppe
483 F.3d 447 (Sixth Circuit, 2007)
United States v. Climmie Jones, Jr.
489 F.3d 243 (Sixth Circuit, 2007)
United States v. David Zobel
696 F.3d 558 (Sixth Circuit, 2012)
United States v. Andrew Johnson
732 F.3d 577 (Sixth Circuit, 2013)
United States v. Bolds
511 F.3d 568 (Sixth Circuit, 2007)
United States v. Brogdon
503 F.3d 555 (Sixth Circuit, 2007)
United States v. Vowell
516 F.3d 503 (Sixth Circuit, 2008)
United States v. Santillana
540 F.3d 428 (Sixth Circuit, 2008)
United States v. Kontrol
554 F.3d 1089 (Sixth Circuit, 2009)
United States v. Jeross
521 F.3d 562 (Sixth Circuit, 2008)
United States v. Simmons
501 F.3d 620 (Sixth Circuit, 2007)
United States v. Camiscione
591 F.3d 823 (Sixth Circuit, 2010)